CG
GYRE icon

Cutler Group’s Gyre Therapeutics GYRE Stock Holding History

Cutler Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,000
Closed -$3K – 4307
2019
Q2 		$3K Buy
+2,000
New +$125K ﹤0.01% 3365
2018
Q4 		– Sell
-267
Closed -$2K – 4185
2018
Q3 		$2K Buy
+267
New +$21.2K ﹤0.01% 3500
2017
Q2 		– Sell
-5,320
Closed -$109K – 6594
2017
Q1 		$109K Buy
+5,320
New +$311K ﹤0.01% 1657

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cutler Group's GYRE Position: Q4 2023 in Review

Cutler Group sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 367 shares — an estimated $2K sold.

Cutler Group first reported a position in GYRE in Q4 2015 and held it in 25 quarters. The position peaked at $313K in Q3 2018. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

  • Cutler Group reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 367 Gyre Therapeutics shares in Q4 2023, an estimated $2K.
  • Cutler Group first reported a position in Gyre Therapeutics in Q4 2015 and held it in 25 quarters.
  • Cutler Group's Gyre Therapeutics position peaked at $313K in Q3 2018.
  • 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.